We use cookies to help us improve the website and your experience using it. You may delete and block all cookies from this site at any time. However, please note this may result in parts of the site no longer working correctly. If you continue without changing your settings we will assume you are happy to receive all cookies on this site.

Close

Immunophenotyping for lymphoid and myeloid malignancies (full clinical details required)

General information

Cell surface markers appropriate to diagnostic information provided (see sections on Acute and Chronic leukaemia panels).

The relevant tests required will be specified for each individual case.

Specimen transport: Samples should be received within 24 hours of collection

Repeat frequency: Post treatment monitoring, suspected relapse and MRD

Special precautions: Samples should be maintained at room temperature

Laboratory information

Reporting units: Percentage of the population of cells of interest

Volume and sample type: 5ml EDTA blood or bone marrow

Method: Flow Cytometry

Turnaround time (calendar days from sample receipt to authorised result): Median - 2, 95th percentile - 7

Clinical information

Indications for the test:

  • Suspected lymphoid/myeloid malignancy
  • To confirm relapse
  • To confirm remission

Factors affecting the test: Specimens should be ideally <24 hours old and never more than 48 hours old

 

Clinical workstation reference: PHENOTYPING

 

(Last updated October 7th 2014)